Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy

Epilepsy is a common neurological disease that affects approximately 50 million people worldwide [1]. It is defined as a disorder of the brain and characterised by an enduring predisposition to generate epileptic seizures [2,3]. Multiple antiepileptic drugs (AEDs) have been developed to try to control seizures in patients with epilepsy; however, 20–30% of patients are still refractory to currently available drug treatments, thus, the development of novel AEDs is required [4–6].

0